# Centro de Investigación Biomédica en Red

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centro-de-investigacion-biomedica-en-red/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 99.7 |
| Citations | 2,971,128 |
| City | Madrid |
| Country | ES |
| Description | Centro de Investigación Biomédica en Red is a research organisation in Madrid, ES. OpenAlex records 26,581 works and 2,971,128 citations for it. 5,235 researchers list it as their most recent affiliation. |
| Homepage | https://www.ciberisciii.es/ |
| OpenAlex ID | https://openalex.org/I4210115082 |
| Researchers | 5,235 |
| ROR ID | https://ror.org/02g87qh62 |
| Type | facility |
| Works | 26,581 |

## University papers

- [A clinical approach to diagnosis of autoimmune encephalitis](https://scholariq.org/papers/a-clinical-approach-to-diagnosis-of-autoimmune-encephalitis/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis](https://scholariq.org/papers/age-as-a-confounding-factor-for-the-accurate-non-invasive-diagnosis-of-advanced/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma](https://scholariq.org/papers/paraneoplastic-encephalitis-psychiatric-symptoms-and-hypoventilation-in-ovarian/)
- [Clinical manifestations of the anti-IgLON5 disease](https://scholariq.org/papers/clinical-manifestations-of-the-anti-iglon5-disease/)
- [European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)](https://scholariq.org/papers/european-contribution-to-the-study-of-ros-a-summary-of-the-findings-and/)
- [Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?](https://scholariq.org/papers/caucasian-lean-subjects-with-non-alcoholic-fatty-liver-disease-share-long-term/)
- [Determinants of the clinical expression of amoxicillin‐clavulanate hepatotoxicity](https://scholariq.org/papers/determinants-of-the-clinical-expression-of-amoxicillin-clavulanate/)
- [Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts](https://scholariq.org/papers/metabolomic-based-noninvasive-serum-test-to-diagnose-nonalcoholic/)
- [Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry](https://scholariq.org/papers/comprehensive-analysis-and-insights-gained-from-long-term-experience-of-the/)

## University top topics

Showing 8 of 25.

- [Adipose Tissue and Metabolism](https://scholariq.org/topics/adipose-tissue-and-metabolism/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Mitochondrial Function and Pathology](https://scholariq.org/topics/mitochondrial-function-and-pathology/)
- [Nutritional Studies and Diet](https://scholariq.org/topics/nutritional-studies-and-diet/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Adipokines, Inflammation, and Metabolic Diseases](https://scholariq.org/topics/adipokines-inflammation-and-metabolic-diseases/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.